Badreddin Edris Biography and Net Worth

Dr. Badreddin Edris is responsible for corporate strategy, business development and capital formation. His professional experience spans private and public equity investing, company formation and operations, corporate and business development, and strategic and product planning in the biotechnology industry. Prior to joining SpringWorks Therapeutics, Badreddin was an investment and operating professional on the private equity team at OrbiMed, where he was involved in deal sourcing, evaluation and execution, as well as post-investment strategic and operational support for biotechnology companies across a range of therapeutic areas and stages of development. Badreddin also co-founded and held operating roles at two OrbiMed portfolio companies, Silverback Therapeutics (where he was Chief Business Officer) and Edgewise Therapeutics (where he was Chief Operating Officer). Before OrbiMed, Badreddin was a management consultant at Bain & Company, where he collaborated with global pharmaceutical and biotechnology companies on a range of strategic and operational projects.

Badreddin received his Ph.D. in genetics from Stanford University, where he was an NSF research fellow.

How old is Badreddin Edris?: Dr. Edris is currently 37 years old. There are 7 older executives and no younger executives at SpringWorks Therapeutics. The oldest executive at SpringWorks Therapeutics is Mr. Herschel S. Weinstein J.D., General Counsel & Secretary, who is 67 years old. Learn More on Badreddin Edris' age.
How do I contact Badreddin Edris?: The corporate mailing address for Dr. Edris and other SpringWorks Therapeutics executives is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. SpringWorks Therapeutics can also be reached via phone at 203-883-9490 and via email at [email protected]. Learn More on Badreddin Edris' contact information.
Has Badreddin Edris been buying or selling shares of SpringWorks Therapeutics?: Badreddin Edris has not been actively trading shares of SpringWorks Therapeutics within the last three months. Most recently, Badreddin Edris sold 32,000 shares of the business's stock in a transaction on Thursday, July 1st. The shares were sold at an average price of $85.35, for a transaction totalling $2,731,200.00. Learn More on Badreddin Edris' trading history.
Who are SpringWorks Therapeutics' active insiders?: SpringWorks Therapeutics' insider roster includes Badreddin Edris (COO), Julie Hambleton (Director), Saqib Islam (CEO), Daniel Pichl (Chief People Officer), L. Smith (Insider), and Stephen Squinto (Director). Learn More on SpringWorks Therapeutics' active insiders.
Are insiders buying or selling shares of SpringWorks Therapeutics?: In the last year, insiders at the sold shares 1 times. They sold a total of 15,000 shares worth more than $751,500.00. The most recent insider tranaction occured on February, 16th when insider Daniel Pichl sold 15,000 shares worth more than $751,500.00. Insiders at SpringWorks Therapeutics own 7.6% of the company. Learn More about insider trades at SpringWorks Therapeutics.
Information on this page was last updated on 2/16/2024.

Badreddin Edris Insider Trading History at SpringWorks Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/1/2021	Sell	32,000	$85.35	$2,731,200.00
1/25/2021	Sell	32,000	$84.07	$2,690,240.00

Badreddin Edris Buying and Selling Activity at SpringWorks Therapeutics

SpringWorks Therapeutics Company Overview

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Today's Range

Now: $36.58

$36.29

$37.55

50 Day Range

MA: $32.57

$28.61

$37.93

2 Week Range

Now: $36.58

$20.19

$53.92

Volume

608,858 shs

Average Volume

996,684 shs

Market Capitalization

$2.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.